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For many years, the standard treatment for stage III colon cancer has been surgical resection followed by 5-fluorouracil in
combination with folinic acid (5-FU/LV). Ongoing clinical trial evidence suggests that capecitabine and oxaliplatin (in combination with
5-FU/LV) may improve disease-free survival and overall survival when compared against 5-FU/LV alone in the adjuvant setting. This
study evaluates the cost-effectiveness profiles of these two regimens in comparison to standard chemotherapy, using evidence from
two international randomised controlled trials. Survival modelling techniques were employed to extrapolate survival curves from the
two trials in order to estimate the long-term benefits of alternative treatment options over the remaining lifetime of patients. The
health economic analysis suggests that capecitabine is expected to produce greater health gains at a lower cost than 5-FU/LV.
Oxaliplatin in combination with 5-FU/LV is estimated to cost d2970 per additional QALY gained when compared to 5-FU/LV alone.
Future research should attempt to elucidate uncertainties concerning the optimal roles of capecitabine and/or oxaliplatin in the
adjuvant setting in order to achieve the maximum level of clinical benefit.
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Cancer of the large bowel is the third most common cancer in the
UK, after breast and lung cancer. In 2002, there were 29547 new
cases registered in England and Wales, which represents over 12%
of all new cancers in the UK (Cooper et al, 2005; Welsh Cancer
Intelligence and Surveillance Unit, 2005). Approximately two
thirds of all newly diagnosed cases of colorectal cancer (CRC)
occur within the colon, and around 26% of these are classified as
stage III (Dukes’ C), in which the cancer has spread to at least one
lymph node (South West Cancer Intelligence Service, 1995).
Approximately 50–60% of patients will suffer a recurrence of
their disease (Benson et al, 2004).
Evidence suggests that patients with stage III colon cancer have
a 5-year survival rate of between 25 and 60% (van Cutsem and
Kataja, 2005). Until recently, the current standard treatment for
patients with stage III colon cancer was surgical resection (with
curative intent) followed by a 6-month course of adjuvant
intravenous 5-fluorouracil in combination with folinic acid (5-
FU/LV) for those patients deemed sufficiently fit to tolerate the
adverse effects of chemotherapy (National Institute for Clinical
Excellence, 2004a). Several 5-FU/LV regimens exist, each of which
may vary in terms of efficacy and adverse event profiles. The once-
weekly bolus QUASAR regimen is most commonly used in
England and Wales, although there is variation between cancer
centres.
More recently, treatment using oxaliplatin (in combination with
5-FU/LV) and capecitabine has been trialled in the adjuvant
treatment of patients with stage III colon cancer. Oxaliplatin is
an intravenously administered, water soluble, platinum-based
cytotoxic compound that forms intra- and inter-strand adducts
with deoxyribose nucleic acid (DNA) leading to cell damage.
Oxaliplatin, in combination with 5-FU/LV, is licensed in the EU for
the adjuvant treatment of stage III colon cancer after complete
resection of the primary tumour, and for the treatment of
metastatic CRC. Capecitabine is an orally administered, non-
cytotoxic fluoropyrimidine carbamate, and is a precursor of 5-FU.
Capecitabine is currently licensed in the EU for the adjuvant
treatment of patients with stage III colon cancer following surgery
and for first-line monotherapy in patients with metastatic CRC.
Within this study, we developed a health economic model to
estimate the marginal cost-effectiveness of oxaliplatin plus 5-FU/
LV and capecitabine in comparison to standard chemotherapy
(5-FU/LV alone) in the treatment of patients with completely
resected stage III colon cancer in England and Wales. The model
synthesises the best available evidence on the costs and
consequences resulting from the use of oxaliplatin and capecita-
bine to inform whether these therapies represent value for money
for the NHS in England and Wales. This study was undertaken to
inform the National Institute for Health and Clinical Excellence’s
(NICE) technology appraisal of oxaliplatin and capecitabine for the
adjuvant treatment of stage III colon cancer (National Institute for
Health and Clinical Excellence, 2006).
METHODS
Model structure and scope
We undertook a systematic review of evidence relating to the
clinical effectiveness of capecitabine and oxaliplatin plus 5-FU/LV
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sin comparison to 5-FU/LV in the adjuvant treatment of stage III
colon cancer (Pandor et al, 2005). Three relevant trials were
identified: (1) the Multi-Centre International Study of Oxaliplatin/
5-FU and leucovorin in the Adjuvant Treatment of Colon Cancer
(MOSAIC) (Andre ´ et al, 2004), (2) The Xelodat Adjuvant
Chemotherapy Trial (X-ACT) (Scheithauer et al, 2003; Twelves
et al, 2005) and (3) the National Surgical Adjuvant Breast and
Bowel Project (NSABP C-07) (Wolmark et al, 2005). Efficacy data
from the NSABP C-07 trial were not mature at the time of writing
and were presented only in abstract form, hence only clinical and
resource use evidence from the MOSAIC and X-ACT studies were
included in the health economic analysis. Both studies were multi-
centre, international randomised controlled trials (RCTs). The
MOSAIC study was designed to evaluate the adjuvant use of
oxaliplatin in combination with infusional 5-FU/LV (FOLFOX4),
compared with infusional 5-FU/LV alone (the LV5FU2 or de
Gramont regimen) in patients with both stage II and stage III colon
cancer. The primary efficacy end point within the MOSAIC trial
was disease-free survival (DFS), whilst secondary end points
included overall survival (OS), safety and long term adverse effects
(Andre ´ et al, 2004). The X-ACT study was designed to demonstrate
that capecitabine monotherapy was at least equivalent to 5-FU/LV
(Mayo Clinic regimen) in terms of DFS when administered as
adjuvant treatment following surgery for stage III colon cancer.
Secondary end points included relapse-free survival, OS, safety
(including treatment toxicity), and quality of life (Scheithauer et al,
2003; Twelves et al, 2005). Table 1 details the four treatment
regimens included in the health economic analysis.
A state transition model was developed using empirical DFS and
OS curves reported within the MOSAIC trial (Andre ´ et al,2 0 0 4 ;d e
Gramont et al, 2005) and the X-ACT trial (Cassidy et al, 2004;
Twelves et al, 2005) to estimate the clinical and cost consequences of
FOLFOX4 and capecitabine over the remaining lifetime of patients.
State transition models are particularly useful for diseases or
conditions whereby risk is ongoing over time, where events
may occur more than once, and where the timing of events is
important (Sonnenberg and Beck, 1993; Briggs and Sculpher, 1998).
Clinically important events such as disease progression and death
are modelled as transitions between health states. The primary
health economic outcomes are the marginal cost per life-year gained
(LYG) and the marginal cost per quality-adjusted life-year (QALY)
gained for FOLFOX4 versus 5-FU/LV (de Gramont regimen), and
for capecitabine vs 5-FU/LV (Mayo Clinic regimen). A simple
schematic of the health economic model is presented in Figure 1.
The model is centred around three health states: alive without
relapse, alive following relapse, and dead. Transitions between
health states were derived from published survival curves using a
4-weekly cycle length. Costs and health outcomes were modelled
according to the number of patients residing within each health
state and the number of patients transiting between health states.
The assumptions which underpin the health economic analysis are
presented in Box 1.
The time-dependent probability of relapse was modelled by
fitting parametric Weibull survivor functions to empirical DFS
curves observed within the MOSAIC (Andre ´ et al, 2004; de
Gramont et al, 2005) and X-ACT (Cassidy et al, 2004; Twelves et al,
2005) studies using regression analysis. This form of extrapolative
modelling was used to predict time-to-event outcomes where
empirical trial data were censored. The model assumes that all
relapses occur within five years following complete resection of the
primary tumour, based upon evidence on the long-term follow-up
of patients with stage III colon cancer undergoing adjuvant
chemotherapy (Moertel et al, 1995). The expected survival of
patients following relapse was modelled using a parametric
Weibull survival model based on the experience of patients
enrolled in the FOCUS trial (Maughan et al, 2005). The long-term
survival of patients who do not relapse was modelled using a UK
life table model (Government Actuary’s Department, 2005); the
model thus assumes that these patients have the same life
expectancy as an age-matched population of individuals with no
history of colon cancer.
Valuation of health outcomes
Health utility scores were not collected within either the X-ACT or
MOSAIC trials. Modelled survival estimates were adjusted to
account for the patient’s level of health-related quality of life using
published colorectal cancer utility estimates. A utility score of 0.7
was assigned to patients receiving adjuvant treatment who
experienced no significant serious adverse effects (Ness et al,
1999), while patients who suffered significant adverse events were
assigned a utility score of 0.63 for the duration of the treatment
course (Ness et al, 1999). Patients who remained disease-free
following adjuvant treatment were assigned a utility score of 0.92
(Ramsey et al, 2000), while patients who relapsed were assigned a
utility score of 0.24 (Ness et al, 1999). In line with recommenda-
tions from NICE at the time of the analysis, health outcomes were
discounted at a rate of 1.5%.
Resource use and costs
The health economic analysis was undertaken from the perspective
of the UK National Health Service (NHS) and Personal Social
Services (PSS). The model includes costs associated with drug
acquisition and administration, pharmacy handling and dispen-
sing, infusor pumps, examinations and tests, as well as hospitalisa-
tion resource use for the management of treatment-related
toxicities. Data concerning chemotherapy usage, dose intensity
and the costs of managing chemotherapy-related toxicities within
the MOSAIC and X-ACT trials were made available by Sanofi-
Synthelabo and Roche Pharmaceuticals. Drug acquisition costs
were obtained from the British National Formulary (Joint
Formulary Committee, 2005). The costs of hospital attendances
and follow-up tests were derived from the NHS Reference Costs
Table 1 Chemotherapy regimens included in the health economic model
Trial Regimen Cycle length (weeks) Cycles per treatment course Total protocol dose per cycle
MOSAIC Oxaliplatin+5-FU/LV 2 12 800mgm
 2 bolus 5-FU
1200mgm
 2 infusional 5-FU
400mgm
 2 leucovorin
85mg/m
2 oxaliplatin
5-FU/LV (de Gramont regimen) 2 12 800mgm
 2 bolus 5-FU
1200mgm
 2 infusional 5-FU
400mgm
 2 leucovorin
X-ACT Capecitabine 3 8 35000mgm
 2 capecitabine
5-FU/LV (Mayo Clinic regimen) 4 6 2125mgm
 2 bolus 5-FU
100mgm
 2 leucovorin
FU, fluorouracil; LV, leucovorin.
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s(Department of Health, 2005). Pharmacy costs were obtained
through personal communication (Michelle Rowe, The Christie
Hospital NHS Trust, 2005). The costs of diagnostic tests and
imaging were obtained from the literature (Mant and Primrose,
2004; Renehan et al, 2004).
The costs associated with relapse were taken from a recent
health economic evaluation of irinotecan and oxaliplatin for the
treatment of metastatic CRC undertaken on behalf of NICE (Hind
et al, 2005). In line with NICE guidance at the time of the analysis,
the model assumes that patients who relapse would be offered
first-line 5-FU/LV, followed upon progression by second-line
single-agent irinotecan (National Institute for Clinical Excellence,
2002). The impact of the expected costs and health outcomes
resulting from the use of more recently recommended regimens of
irinotecan, oxaliplatin and 5-FU/LV (based on our analysis of data
from the GERCOR trial by Tournigand et al, 2004) for the
treatment of metastatic CRC were explored within the sensitivity
analysis. Further details of all cost parameters are available within
the full study report (Pandor et al, 2005). All costs were valued at
2004 prices and discounted at a rate of 6%.
Sensitivity analysis
A number of one-way sensitivity analyses were undertaken to
explore the impact of alternative parametric assumptions on the
central estimates of cost-effectiveness. These included alternative
assumptions concerning discount rates for costs and health
outcomes, alternative utility scores for patients who suffer a
relapse and for those who remain disease-free, and assumptions
concerning the impact of recent changes to guidance on the use of
cytotoxic regimens for metastatic disease. Structural sensitivity
analyses were also undertaken to explore the impact of alternative
durations over which patients may relapse on cost-effectiveness
estimates, as well as the impact of assuming a 5-year time horizon
for the evaluation of costs and health outcomes.
Probabilistic sensitivity analysis was undertaken to generate
information on the probability that each intervention produces the
greatest level of net benefit (Claxton et al, 2005). Each model
parameter was assigned a unique probability distribution based
upon published estimates of uncertainty. This joint uncertainty
was then propagated through the model using Monte Carlo
sampling techniques to generate distributions of lifetime costs and
health outcomes for patients receiving each treatment regimen.
The results of the probabilistic sensitivity analysis are presented as
marginal cost-effectiveness planes. Further details of the modelling
methods and data sources used within this study are available from
the full study report (Pandor et al, 2005).
RESULTS
Central estimates of cost-effectiveness
Table 2 presents the expected costs and health outcomes for each
of the four interventions. Estimates of discounted LYGs are shown
in parentheses.
Table 2 suggests that capecitabine is expected to result in cost-
savings of approximately d3320 per patient in comparison with the
Mayo Clinic 5-FU/LV regimen, while also providing an additional
0.98 QALYs over the 50-year model time horizon; in other words,
capecitabine is expected to dominate 5-FU/LV. FOLFOX4 is
tp1 tp3 tp6
tp2 tp4
tp5
Alive without 
relapse
Alive following
relapse
Dead
tp=transition probability of progression. 
tp1 and tp2 were estimated using fitted DFS curves from the MOSAIC (de Gramont et  al, 2005; André et al, 
2004) and X-ACT (Twelves et al, 2005; Cassidy et al, 2004) trials.
tp3 and tp4 were estimated from fitted Weibull functions based on OS data from the FOCUS trial (Medical 
Research Council, 2003) within the base−case analysis. The impact of using OS and cost 
estimates based on a trial of FOLFOX/FOLFIRI and FOLFIRI/FOLFOX (Tournigand et al, 2004) was 
assessed within the sensitivity analysis. 
tp5 was estimated from a Gompertz regression model of OS in the general UK population 
(Government Actuary's Department, 2005). 
tp6=1. 
Figure 1 Schematic of health economic model.
Box 1 Key assumptions of the health economic model
K Survival following relapse is assumed to be independent of time of relapse and adjuvant treatment received (e.g. patients relapsing after FOLFOX4 are assumed
to still have the same treatment options and expected survival as those relapsing after 5-FU/LV). While earlier relapse may indicate more aggressive disease and
a poorer prognosis, without patient-level data this assumption is inevitable
K The survival of patients following relapse is assumed to be equivalent to survival of patients enrolled within the FOCUS trial
K All relapses are assumed to occur within five years following resection of the primary tumour. Clinical evidence from long-term follow-up of patients undergoing
adjuvant chemotherapy supports this assumption (Moertel et al, 1995). The impact of this assumption on the central estimates of cost-effectiveness was tested
within the sensitivity analysis
K Patients with subsequent metastatic disease are assumed to receive first-line 5-FU/LV followed upon progression by single-agent irinotecan
K In line with the administration schedule used in the MOSAIC trial (Andre ´ et al, 2004), patients receiving 5-FU/LV via the de Gramont regimen are assumed to
receive their treatment on an outpatient basis
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sestimated to produce an additional 1.32 QALYs at an additional
cost of d3941 in comparison with the de Gramont 5-FU/LV
regimen; the marginal cost-effectiveness of FOLFOX4 versus the de
Gramont 5-FU/LV regimen is estimated to be d2970 per additional
QALY gained.
Importantly, the MOSAIC trial used the de Gramont 5-FU/LV
regimen as the control arm. While this regimen is not commonly
used in the adjuvant treatment of colon cancer in the UK, direct
evidence suggests that bolus and infusional 5-FU/LV are similar
in terms of overall survival, albeit with fewer adverse events
associated with the infusional regimens. If the Mayo Clinic
regimen is assumed to have the same efficacy as the De Gramont
regimen, the mean incremental cost-effectiveness of FOLFOX4
compared with the Mayo Clinic regimen would be around d10000
per QALY gained. Similarly, such indirect comparisons suggest
that FOLFOX4 vs capecitabine is expected to cost approximately
d12874 per additional QALY gained. However, as there are no
RCTs, which have included either of these comparisons in the
adjuvant treatment of stage III colon cancer, conclusions based
upon such indirect comparisons should be approached tentatively.
Uncertainty analysis
One-way and structural sensitivity analysis Table 3 presents the
results of the one-way and structural sensitivity analysis.
The sensitivity analysis suggests that the central estimates of
cost-effectiveness are robust to changes in individual parameter
values. The model suggests that capecitabine is consistently
expected to dominate 5-FU/LV (Mayo Clinic regimen), and that
the marginal cost-effectiveness of FOLFOX4 versus 5-FU/LV (de
Gramont regimen) is no higher than approximately d17000 per
QALY gained, even when no further benefits are assumed to accrue
beyond the duration of the MOSAIC trial.
Probabilistic sensitivity analysis Figure 2 presents a cost-effec-
tiveness plane showing the marginal costs and QALYs associated
with capecitabine in comparison to the Mayo Clinic 5-FU/LV
regimen.
Figure 2 suggests that capecitabine is consistently expected to
result in cost-savings and provide additional health gains when
compared to bolus 5-FU/LV. The uncertainty analysis suggests that
the probability that capecitabine has a marginal cost-effectiveness
that is better than d20000 per QALY gained is estimated to be
approximately 0.998 when compared to 5-FU/LV.
Figure 3 presents a marginal cost-effectiveness plane describing
the marginal costs and QALYs gained for FOLFOX4 vs the de
Gramont 5-FU/LV regimen.
Figure 3 suggests that FOLFOX is expected to produce greater
health gains than 5-FU/LV albeit at a greater cost. The probability
that FOLFOX has a marginal cost-effectiveness that is better than
d20000 per QALY gained is estimated to be approximately 0.997
when compared to 5-FU/LV.
DISCUSSION
The health economic analysis presented within this study suggests
that both capecitabine and FOLFOX4 are expected produce health
gains at a cost which is currently considered acceptable to the NHS
in England and Wales (NICE, 2004b; NICE, 2006). The health
economic model suggests that capecitabine is expected to be more
effective and less expensive than 5-FU/LV, while the marginal cost-
effectiveness of FOLFOX4 versus 5-FU/LV is estimated to be below
d3000 per QALY gained. As with any health economic model,
Table 2 Summary of cost-effectiveness results
Adjuvant treatment
option
Mean
discounted
QALYs (LYGs)
Mean
discounted
costs
5-FU/LV (Mayo Clinic) 8.47 (9.87) d13239
Capecitabine 9.45 (10.88) d9919
Difference 0.98 (1.02)  d3320
Marginal cost per QALY
gained (capecitabine versus
Mayo Clinic regimen)
Dominating
5-FU/LV (de Gramont) 9.39 (10.80) d22261
FOLFOX4 10.71 (12.15) d26202
Difference 1.33 (1.36) d3940
Marginal cost per QALY
gained (FOLFOX4 versus
de Gramont regimen)
d2970
FU¼fluorouracil; LV¼leucovorin; QALY¼quality adjusted life year; LYG¼life year
gained.
Table 3 Sensitivity analysis results
Parameter Value in base-case analysis Value in sensitivity analysis
Cost per QALY gained
(capecitabine versus
bolus 5-FU/LV)
Cost per QALY gained
(FOLFOX4 versus
infusional 5-FU/LV)
Base case — — Dominating d2970
Discount rates for costs and
health outcomes
6% for costs, 1.5% for health
outcomes
3.5% for costs and health outcomes
(NICE, 2004b)
Dominating d3723
Discount rates for costs and
health outcomes
6% for costs, 1.5% for health
outcomes
Undiscounted Dominating d2364
Utility for patients with relapse 0.24 (Ness et al, 1999) 0.575 (Petrou and Campbell, 1997) Dominating d3069
Utility for patients with relapse 0.24 (Ness et al, 1999) 0.1 (Petrou and Campbell, 1997) Dominating d2930
Utility for patients without
relapse
0.92 (Ramsey et al, 2000) 0.5 (assumption) Dominating d5584
Costs and outcomes for
relapsers based on FOLFOX/
FOLFIRI sequence
Cost¼d9638 (Hind et al, 2005)
QALYs¼1.38 (Hind et al, 2005)
Cost¼d21742 (Hind et al, 2005)
QALYs¼2.28 (Hind et al, 2005)
Dominating d1679
Costs and outcomes for
relapsers based on FOLFIRI/
FOLFOX sequence
Cost¼d9638 (Hind et al, 2005)
QALYs¼1.38 (Hind et al, 2005)
Cost¼d22746 (Hind et al, 2005)
QALYs¼2.14 (Hind et al, 2005)
Dominating d1565
Assumed duration over which
relapses may occur
a
5-years 10-years Dominating d1963
Time horizon
a 50-years Within-trial analysis (5-year horizon) Dominating d17115
FU¼fluorouracil; LV¼leucovorin; QALY¼quality adjusted life year.
aStructural sensitivity analysis.
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sthe data used to inform the analysis is subject to uncertainty
and assumptions are required in the absence of empirical clinical
evidence. However, the sensitivity analyses demonstrate that
capecitabine is consistently expected to dominate the Mayo 5-
FU/LV regimen, irrespective of assumptions concerning discount
rates, utility scores as well as structural assumptions concerning
the natural history of the disease (see Table 3). The marginal cost-
effectiveness of FOLFOX4 vs 5-FU/LV also remains favourable
when conservative parameter values are assumed.
Very few previous studies have attempted to estimate the cost-
effectiveness of capecitabine and oxaliplatin plus 5-FU/LV in the
adjuvant setting. Douillard et al (2004) conducted an economic
analysis of capecitabine using data from the X-ACT study, and
concluded that capecitabine would save an average of d1864 per
patient compared with 5-FU/LV, and would offer a survival benefit
of 8.7 additional quality-adjusted life-months (approximately 0.73
additional QALYs). This study used different assumptions
concerning relapse-free and OS benefits beyond the duration of
the trial. Koperna and Semmler (2003) reported a cost per LYG of
h12485 (approximately d8500) per LYG for oxaliplatin in
combination with 5-FU/LV vs 5-FU/LV. However, this study used
data from trials of oxaliplatin in patients with metastatic colorectal
cancer as the basis for estimating survival outcomes for patients
with stage III disease in the adjuvant setting. Aballea et al (2005)
conducted an economic analysis of FOLFOX4 and 5-FU/LV using
data from the MOSAIC trial, and reported a cost per LYG of US
$27300 (approximately d14560). As this study has been published
only in abstract form, it is difficult to pinpoint the key differences
between our model and the economic analysis reported by Aballea
et al. It is reasonable to suggest that these differences are a result of
the omission of health-related quality of life information, the use of
equivalent discount rates for both costs and health outcomes, and
the adoption of a US Medicare perspective.
Importantly, there are limitations surrounding the use of
evidence from the MOSAIC and X-ACT studies to inform policy
decisions concerning clinically effective and cost-effective treat-
ment options for patients with colon cancer in England and Wales.
Notably, patients enrolled within these trials were comparatively
younger than the typical CRC population treated on the NHS;
patients in both studies had a mean age of around 60 years, while
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sthe median age of diagnosis of colon cancer is over 70 years
(Cooper et al, 2005; Rowan et al, 2005; Welsh Cancer Intelligence
and Surveillance Unit, 2005), hence the long-term survival benefits
associated with each intervention may have been overestimated
within the model. This bias may potentially result in optimistic
marginal cost-effectiveness estimates for both FOLFOX4 and
capecitabine. Evidence from a meta-analysis of trials in the
adjuvant setting (Matasar et al, 2004), which conducted separate
analyses for patients aged 70 years or under and those aged above
70 years, suggests that there is no significant difference in either
OS or DFS at 8 years post-randomisation. However, the distribu-
tion of patient ages within each group was not reported, and it is
unclear whether the survival curves presented in the Matasar et al
(2004) study included all-cause mortality within the DFS curves. It
is also noteworthy that the long term impact of oxaliplatin plus 5-
FU/LV on neuropathy and its associated relationship with health-
related quality of life is not currently known; given the absence of
evidence, this economic analysis dues not explicitly address this issue.
The key assumption employed within the health economic
model is that the short-term survival benefits of capecitabine and
FOLFOX4 translate into long-term health gains; in other words,
benefits accrued in the short-term are assumed to be sustained in
the long-term. The absence of empirical long-term evidence makes
this assumption difficult to validate, hence survival modelling
methods were required to estimate long-term disease outcomes.
The accuracy of these methods will only become clear once long-
term survival data from the X-ACT and MOSAIC studies becomes
available. A recent analysis of data from over 20000 patients in 18
randomised trials of FU-based adjuvant therapy concluded that a
difference in 3-year DFS is a strong predictor of 5-year OS benefit,
which would broadly support the assumptions made in our model
(Sargent et al, 2005). However, it is possible that the incremental
benefit of oxaliplatin could be lessened if oxaliplatin pretreatment
affects subsequent treatment choices and/or efficacy in relapsed
patients. Similarly, long-term neurotoxicity following oxaliplatin
therapy could impact upon a patient’s health-related quality of life
and profoundly affect QALY gains, but this can only be assessed
using long-term follow-up data.
The implications of the X-ACT and MOSAIC data for clinical
decision-making are complex. In particular, while each trial has
demonstrated clinical and cost benefit for the intervention under
assessment (the substitution of capecitabine in place of 5-FU/LV;
addition of oxaliplatin) the trials do not clarify whether one or
other of the two, or both, interventions should be adopted for
maximum benefit. Evidence from further trials, including trials
using oxaliplatin/capecitabine combinations may help to clarify
these issues. Meanwhile, since oxaliplatin plus capecitabine is not
currently licensed in the adjuvant setting, oncologists will need to
evaluate the costs and benefits of the available treatment options
for individual patients.
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